The agreement will use Ablynx’ Nanobodies, a novel class of therapeutic proteins which combine the beneficial features of conventional antibodies, with desirable properties of small-molecule drugs. In addition, Boehringer Ingelheim will commence a joint research program including Ablynx scientists.
Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialization of any products resulting from the collaboration. The deal includes an upfront fee, development and commercial milestones. Ablynx will also receive undisclosed royalties based on net sales.
Dr Edwin Moses, CEO of Ablynx, said: “Boehringer Ingelheim have developed considerable expertise in the field of neurological diseases including Alzheimer’s disease and combined with their biologic biopharmaceutical capabilities we believe they are the ideal partner to ensure that we maximize the therapeutic potential of Nanobodies.”